INDGN/SE/2026-27/47

Meeting Participants

Board Members Present:

  • Dr. Rajesh Bhaskaran Nair (Non-Executive Director)
  • Mr. Jairaj Manohar Purandare (Non-Executive Independent Director, Chairman of Audit Committee and Stakeholders Relationship Committee)
  • Mr. Krishnamurthy Venugopala Tenneti (Non-Executive Independent Director, Chairperson of Nominations and Remuneration Committee and Investment Committee)
  • Mr. Pravin Rao (Non-Executive Independent Director)
  • Ms. Georgia Nikolakopoulou Papathomas (Non-Executive Independent Director)
  • Ms. Jill Mary DeSimone (Non-Executive Independent Director)
  • Dr. Sanjay Suresh Parikh (Executive Director and Executive Vice President, Chairperson of Risk Management Committee)
  • Mr. Manish Gupta (Chairman, Executive Director, and Chief Executive Officer)

Management Present:

  • Mr. Suhas Prabhu (Chief Financial Officer)
  • Ms. Srishti Ramesh Kaushik (Company Secretary and Compliance Officer)

Key Financial Performance Highlights (FY2025-26)

  • Revenue: ₹35,105 million (USD 396.9 million), representing 23.6% growth year-on-year
  • EBITDA: ₹6,247 million, representing 11.1% growth year-on-year
  • Profit After Tax: ₹4,011 million
  • Operating Cash Flow: Approximately ₹650 crores generated
  • Bank Balances and Current Investments: ₹1,481 crores
  • Debt Position: Company remains debt-free
  • Dividend: Board recommended final dividend of ₹2.25 per share

Segment Performance

  • Enterprise Commercial Solutions: Revenue grew ~27.0% to ₹2,461 crores
  • Enterprise Medical Solutions: Revenue grew ~16.0% to ₹930 crores

Client Metrics

  • Active Clients: Increased from 73 to 91
  • Clients above $1 Million Revenue: Increased from 41 to 53
  • Revenue Concentration: Top 5 customers constitute ~30% of revenue; largest customer <10% of revenue
  • Geographic Revenue Mix: North America (74-75%), Europe (22%), Rest of World including India (2.5%)

Strategic Acquisitions Completed

1. BioPharm (October 2025): Acquired for approximately ₹882 crores (USD 104 million)

  • USD 65 million paid at closing
  • Subsequent payment upon completion of certain milestones
  • Pending earn-out payment of USD 19 million due in 2027
  • Added advanced AI and digital advertising capabilities
  • Integration completed one month ahead of schedule

2. Warn & Company and Cake Kommunikations: Enhanced European market presence with deep local expertise

AI Strategy and Technology Platform

Company detailed its AI-native operating system built on four layers:

1. Intelligent Data Layer: Drawing on over 3 million HCP engagement signals and two decades of commercial content

2. Cortex: Proprietary LLM-agnostic reasoning engine encoding 27 years of domain expertise

3. Expert AI Agents: Mesh of production-grade AI agents across workflows

4. Domain Expert Orchestration: Regulated judgment and accountability

AI Implementation Examples:

  • One-Click Submissions compressing regulatory processes from months to days
  • Agentic AOR for centralized content creation and activation
  • Human-less MLR turning medico-legal reviews from bottleneck to near-instantaneous
  • Safety-in-a-Box automating adverse event processing
  • AI-powered omnichannel engagement for personalized HCP interactions
  • Intelligent Clinical Trial Operations accelerating trial design

Scale Metrics: Reviewed over 65,000 MLR assets in 2025

Operational Metrics

  • Global Workforce: Over 5,500 professionals across 11 countries and 19 offices
  • Delivery Teams: 4,900+ professionals
  • Women Representation: 47% of global workforce
  • Revenue per Employee: USD 75,000 (highest among peers)
  • Net Revenue Retention: Above 100.0% for 5 consecutive years

ESG and Community Initiatives

  • ESG Ratings: EcoVadis silver rating; CyberVadis platinum rating (score 963/1000)
  • CSR Focus: Strengthening India's deep science ecosystem through partnerships with C-CAMP, Ashoka University, Plaksha University
  • Additional Support: Olympic and Paralympic athletes, palliative care, foundational education, school nutrition

Auditor Reports

  • Statutory Auditors: Deloitte Haskins & Sells issued unqualified opinion on standalone and consolidated financial statements
  • Secretarial Auditor: Qualifications in secretarial audit report (Annexure 3 to Board's report) with management response provided

Resolutions Presented for Voting

1. Adoption of Financial Statements for year ended March 31, 2026

2. Declaration of Final Dividend

3. Appointment of Mr. Manish Gupta (DIN: 00219273) as Director liable to retire by rotation

4. Appointment of Dr. Sanjay Suresh Parikh (DIN: 00219278) as Director liable to retire by rotation

5. Appointment of Ms. Jill Mary DeSimone (DIN: 11483134) as Independent Director

Q&A Session Highlights

Margin Outlook: Management expects EBITDA margins to return to 19-20% range by Q4 FY27 due to:

  • Normalization of growth investments (150 bps impact)
  • Revenue recognition from large outcome-based deal signed December 2025 (1-1.5% impact)
  • Reduction in amortization charge by ~₹50 crores per quarter starting Q3 FY27

Capital Allocation Priorities:

  • Capex expected at ~1% of revenues in FY27 (largely compute devices and servers)
  • Continued focus on strategic acquisitions in commercialization lifecycle areas
  • Disciplined approach to acquisition returns and integration

Growth Strategy:

  • Deepen client relationships and expand enterprise engagements
  • Progress client pyramid: target $50M+ clients, more $25M+ clients
  • Invest in AI platforms and domain expertise
  • Extend presence across therapeutic areas and geographies
  • Translate investments into margin expansion

Geographic Revenue: North America (74-75%), Europe (22%), Rest of World (2.5%)

Voting Process

  • Remote e-voting administered by NSDL
  • Scrutinizer: Mr. Madhvesh K, Practicing Company Secretary
  • Results to be declared within two days and placed on company website, NSDL website, and communicated to stock exchanges